Tianjin Tianyao Pharmaceuticals Co. Ltd. has disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of systemic inflammatory response syndrome (SIRS), autoimmune disease, lung and kidney injury and sepsis.